Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4678)	7/1/1998 9:30:00 AM
From: sam	Respond to of 6136

briefing.newsalert.com

To: Peter Singleton who wrote (4678)	7/1/1998 1:55:00 PM
From: Vector1	Respond to of 6136

Peter, My understanding is that JE-2147 was licensed by AGPH because in vitro, it was fully active against a battery of virus strains representing the predominant resistance mutations produced by currently available PIs. It has also shown synergistic activity in vitro with Viracept, Crixivan, Norvir and other PIs. AGPH plans to initiate Phase I clinical studies on the compound in ealy 99. Shiongi's S-1153 is further along. It is in Phase I/II and is a supposedly highly potent Non-nucleoside reverse transcriptase inhibitor like Sustiva which has shown in vitro activity against common resistance mutations including ones that Sustiva has shown no activity against. You have to love the strategy. It they don't have it they are buying it. These guys are going for it big time and I am going along for the ride V1.